Repligen Corp. (RGEN) Shares Down 3.5%
Repligen Corp. (NASDAQ:RGEN) shares traded down 3.5% during trading on Thursday . The company traded as low as $26.76 and last traded at $26.76, with a volume of 78,924 shares traded. The stock had previously closed at $27.73.
A number of research analysts have commented on the company. Jefferies Group restated a “hold” rating and set a $28.00 price objective on shares of Repligen Corp. in a research note on Monday, June 13th. Zacks Investment Research cut Repligen Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, June 8th.
The firm has a market cap of $917.31 million and a price-to-earnings ratio of 113.63. The stock has a 50 day moving average price of $24.28 and a 200 day moving average price of $25.34.
Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, May 5th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.02. During the same period last year, the firm earned $0.12 earnings per share. The firm had revenue of $25.10 million for the quarter, compared to analyst estimates of $22.54 million. Repligen Corp.’s revenue for the quarter was up 20.5% compared to the same quarter last year. On average, equities research analysts predict that Repligen Corp. will post $0.47 EPS for the current year.
In other news, VP Howard Benjamin sold 2,889 shares of the company’s stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $26.72, for a total value of $77,194.08. Following the transaction, the vice president now directly owns 18,626 shares of the company’s stock, valued at $497,686.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 28th. The stock was sold at an average price of $24.59, for a total transaction of $245,900.00. Following the completion of the transaction, the director now directly owns 27,094 shares in the company, valued at $666,241.46. The disclosure for this sale can be found here.
Several institutional investors recently bought and sold shares of RGEN. Globeflex Capital L P increased its position in Repligen Corp. by 50.6% in the fourth quarter. Globeflex Capital L P now owns 36,153 shares of the company’s stock worth $1,023,000 after buying an additional 12,153 shares during the period. Rhumbline Advisers increased its position in Repligen Corp. by 9.4% in the fourth quarter. Rhumbline Advisers now owns 57,619 shares of the company’s stock worth $1,630,000 after buying an additional 4,970 shares during the period. California State Teachers Retirement System increased its position in Repligen Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 60,884 shares of the company’s stock worth $1,722,000 after buying an additional 984 shares during the period. Russell Frank Co increased its position in Repligen Corp. by 12.7% in the fourth quarter. Russell Frank Co now owns 66,506 shares of the company’s stock worth $1,933,000 after buying an additional 7,498 shares during the period. Finally, Nationwide Fund Advisors increased its position in Repligen Corp. by 14.4% in the fourth quarter. Nationwide Fund Advisors now owns 82,025 shares of the company’s stock worth $2,320,000 after buying an additional 10,350 shares during the period.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.